|
Aug 9
|
Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%
|
|
Aug 6
|
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
|
|
Aug 6
|
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 6
|
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 6
|
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Aug 6
|
OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee
|
|
Aug 5
|
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 1
|
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
|
|
Jun 16
|
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
|
|
Mar 10
|
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
|
|
Jan 2
|
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 25
|
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
|
|
Jun 27
|
Immunome Appoints Phil Tsai as Chief Technical Officer
|
|
May 14
|
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 14
|
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 8
|
Immunome to Present at 2024 Bank of America Healthcare Conference
|
|
May 2
|
Immunome Appoints Kinney Horn as Chief Business Officer
|
|
Apr 26
|
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
|
|
Apr 25
|
Immunome Appoints Sandra M. Swain to Board of Directors
|
|
Apr 5
|
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
|